Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2009

View Archived Issues

Novel Raf kinase B inhibitors claimed by Wyeth

Novel inhibitors of sirtuin described by MethylGene for cancer treatment

Dr Reddy's Laboratories claims novel tetracycline derivatives as antiinfective agents

Amgen and Epix Pharmaceuticals claim novel compounds for the treatment of autoimmune conditions

Activity of HCV p7 ion channel activity inhibitor BIT-225 described

First-in-human phase I/II trial results with adenoviral-based gene transfer for HF published

Cannabinoid CB2 modulators claimed by Kalypsys as analgesics

Impax provides clinical update on IPX-066 and IPX-056

Forest and Cypress launch Savella for fibromyalgia

Novel fumagillin-derived polymer displays in vitro antiangiogenic and in vivo antitumor activity

GlaxoSmithKline presents data on GSK-1838705A, an oncolytic IGF-1R inhibitor

GlaxoSmithKline launches alli in Europe for weight loss

Activity of EGFR, HER2 inhibitor S-222611 delineated in vitro and in vivo

Peregrine reports preliminary phase II data for bavituximab in lung cancer

Snapshots: Recent results from clinical studies of telaprevir in hepatitis C

Phytopharm initiates safety and tolerability study of PYM-50028 in PD

Psylin Neurosciences begins development of PSN-004 for depression

Tolarex receives approval to initiate phase I/IIa trial of a treatment for GVHD

Immuron will acquire immune modulation technology from Hadassah Medical Center

GSK and Stiefel agree to create specialist dermatology business

Pharmasset voluntarily terminates phase III QUASH clinical trials of clevudine in hepatitis B

Amira initiates phase I trial for novel DP2 antagonist, AM-211

Ardea Biosciences reports positive results from a phase I hyperuricemia study

Elusys' anthrax anti-toxin, Anthim, enters second phase I trial

Merck Serono launches Kuvan in Europe

Sanofi-aventis launches Apidra SoloSTAR insulin delivery device in the U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...